Login to Your Account



ActoGeniX Series B to Move IBD Program to IND Stage

By Marie Powers
Staff Writer

Wednesday, April 24, 2013
ActoGeniX NV closed a Series B equity financing round, raising €€10.7 million (US$14 million) to move its ActoBiotics program to the investigational new drug application (IND) stage in a second indication of inflammatory bowel disease (IBD).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription